Paclitaxel Clinical Trials

• Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas
  ClinicalTrials.gov Identifier: NCT00004057 - Active, not recruiting
  Cancer
  
• Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
  ClinicalTrials.gov Identifier: NCT00003644 - Active, not recruiting
  ovarian epithelial cancer
  
• Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients with Advanced Cancer
  ClinicalTrials.gov Identifier: NCT00100139 - Active, not recruiting
  Neoplasm
  
• Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma
  ClinicalTrials.gov Identifier: NCT00193531 - Active, not recruiting
  Neuroendocrine Carcinoma
  
• Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women with Platinum-Resistant Ovarian Cancer
  ClinicalTrials.gov Identifier: NCT00102622 - Active, not recruiting
  Ovarian Cancer
  
• Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
  ClinicalTrials.gov Identifier: NCT00004863 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-Line Treatment of Ovarian Cancer
  ClinicalTrials.gov Identifier: NCT00281515 - Active, not recruiting
  Epithelial Ovarian Cancer
  
• Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer
  ClinicalTrials.gov Identifier: NCT00003050 - Active, not recruiting
  Breast Cancer
  
• Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00006018 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• A Phase 3 Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00373256 - Recruiting
  Breast Neoplasms
  
• Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00254891 - Active, not recruiting
  Carcinoma, Non-Small-Cell Lung
  
• Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00174434 - Active, not recruiting
  Breast neoplams
  
• STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma
  ClinicalTrials.gov Identifier: NCT00084214 - Active, not recruiting
  Melanoma
  
• Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00096668 - Active, not recruiting
  Breast Cancer
  
• Study of Lapatinib in Combination with Paclitaxel in the Treatment of Newly Diagnosed Inflammatory Breast Cancer
  ClinicalTrials.gov Identifier: NCT00111787 - Active, not recruiting
  Breast Cancer
  
• Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients with Advanced Cancer
  ClinicalTrials.gov Identifier: NCT00080418 - Active, not recruiting
  Neoplasm
  
• Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00003327 - Active, not recruiting
  Nose Cancer; Oral Cancer
  
• A Three Arm Study of Adriamycin, Cyclophosphamide Plus Docetaxel vs Adriamycin Plus Cyclophosphamide Followed By Paclitaxel vs Adriamycin Plus Cyclophosphamide Followed By Paclitaxel and Gemcitabine in Adjuvant Breast Cancer
  ClinicalTrials.gov Identifier: NCT00191958 - Active, not recruiting
  Breast Neoplasms
  
• Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma
  ClinicalTrials.gov Identifier: NCT00003350 - Active, not recruiting
  epidemic Kaposi's sarcoma
  
• Paclitaxel or Polyglutamate Paclitaxel in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00108745 - Recruiting
  ovarian epithelial cancer; peritoneal cavity cancer
  
• Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients with Advanced Transitional Cell Cancer of the Bladder
  ClinicalTrials.gov Identifier: NCT00136175 - Active, not recruiting
  Bladder Cancer
  
• Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate
  ClinicalTrials.gov Identifier: NCT00151060 - Active, not recruiting
  Prostate Cancer
  
• Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00054210 - Active, not recruiting
  recurrent non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer
  
• Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00100789 - Active, not recruiting
  Head and Neck Cancer
  
• STA-4783 With Paclitaxel Versus Paclitaxel Alone in Melanoma
  ClinicalTrials.gov Identifier: NCT00522834 - Recruiting
  Melanoma
  
• Paclitaxel in Treating Women With Recurrent Solid Tumors
  ClinicalTrials.gov Identifier: NCT00003130 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
  ClinicalTrials.gov Identifier: NCT00030368 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma
  ClinicalTrials.gov Identifier: NCT00003008 - Active, not recruiting
  epidemic Kaposi's sarcoma; recurrent Kaposi's sarcoma
  
• Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer
  ClinicalTrials.gov Identifier: NCT00004173 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Paclitaxel With Or Without GW572016 As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00075270 - Active, not recruiting
  Metastatic breast cancer
  
• Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer
  ClinicalTrials.gov Identifier: NCT00002939 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Open Label Randomized Neoadjuvant Chemotherapy (Paclitaxel Followed by FEC) Versus Paclitaxel and RAD001 Followed by FEC in Women With Triple Receptor-Negative Breast Cancer
  ClinicalTrials.gov Identifier: NCT00499603 - Recruiting
  Breast Cancer
  
• Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00002937 - Active, not recruiting
  recurrent breast cancer
  
• Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00551733 - Recruiting
  Lung Cancer
  
• Erlotinib (Tarceva) vs. Standard Chemotherapy (Paclitaxel and Carboplatin) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and ECOG PS 2
  ClinicalTrials.gov Identifier: NCT00085839 - Active, not recruiting
  Non-Small Cell Lung Carcinoma
  
• A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients with Lung Cancer
  ClinicalTrials.gov Identifier: NCT00152477 - Active, not recruiting
  Carcinoma, Non-Small-Cell Lung
  
• Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors
  ClinicalTrials.gov Identifier: NCT00003555 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00002628 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Pazopanib Plus Paclitaxel (TAXOL) And Pazopanib Plus Paclitaxel(TAXOL) Plus Carboplatin (PARAPLATIN)
  ClinicalTrials.gov Identifier: NCT00388076 - Recruiting
  Solid Tumors
  
• 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
  ClinicalTrials.gov Identifier: NCT00016874 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum
  ClinicalTrials.gov Identifier: NCT00003160 - Active, not recruiting
  stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; recurrent ovarian epithelial cancer; peritoneal cavity cancer; ...
  
• Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
  ClinicalTrials.gov Identifier: NCT00039780 - Active, not recruiting
  Breast Neoplasms; Breast Diseases; Metastases, Neoplasm
  
• Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer
  ClinicalTrials.gov Identifier: NCT00003379 - Active, not recruiting
  Cervical Cancer
  
• Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer
  ClinicalTrials.gov Identifier: NCT00004077 - Active, not recruiting
  Testicular Cancer; Reproductive Cancer
  
• Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00003539 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00022217 - Active, not recruiting
  Nose Cancer; Oral Cancer; Throat Cancer
  
• Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer
  ClinicalTrials.gov Identifier: NCT00002894 - Active, not recruiting
  recurrent ovarian epithelial cancer; peritoneal cavity cancer
  
• Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00002953 - Active, not recruiting
  stage IV breast cancer
  
• Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer
  ClinicalTrials.gov Identifier: NCT00022620 - Active, not recruiting
  recurrent endometrial cancer; endometrial papillary carcinoma
  
• Paclitaxel Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
  ClinicalTrials.gov Identifier: NCT00031577 - Active, not recruiting
  untreated childhood brain stem glioma
  
• Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
  ClinicalTrials.gov Identifier: NCT00005635 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00005046 - Active, not recruiting
  recurrent ovarian epithelial cancer; peritoneal cavity cancer
  
• FAC Vs.FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative Hight Risk Breast Cancer Patients.
  ClinicalTrials.gov Identifier: NCT00129389 - Recruiting
  Breast cancer.
  
• Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer
  ClinicalTrials.gov Identifier: NCT00004013 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00025688 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors
  ClinicalTrials.gov Identifier: NCT00072215 - Active, not recruiting
  extragonadal germ cell tumor; Testicular Cancer
  
• Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer
  ClinicalTrials.gov Identifier: NCT00536939 - Recruiting
  Breast Cancer
  
• Comparison of Cisplatin Combined With Either Paclitaxel or Gemcitabine in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
  ClinicalTrials.gov Identifier: NCT00057928 - Active, not recruiting
  recurrent cervical cancer; stage IVB cervical cancer
  
• Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
  ClinicalTrials.gov Identifier: NCT00022633 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00003035 - Active, not recruiting
  stage IIIB breast cancer; stage IIIA breast cancer
  
• Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00255762 - Active, not recruiting
  Recurrent Melanoma; Stage IV Melanoma
  
• Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00004265 - Active, not recruiting
  recurrent non-small cell lung cancer
  
• Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction
  ClinicalTrials.gov Identifier: NCT00107341 - Active, not recruiting
  Adenocarcinoma of the Esophagus; stage IV esophageal cancer; recurrent esophageal cancer
  
• Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00004979 - Active, not recruiting
  unspecified adult solid tumor, protocol specific; Quality of Life
  
• Paclitaxel and Capecitabine in Treating Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00005649 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Phase I Trial of Paclitaxel With Perifosine
  ClinicalTrials.gov Identifier: NCT00399126 - Active, not recruiting
  Neoplasms
  
• DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00024414 - Active, not recruiting
  adenocarcinoma of the prostate; stage IV prostate cancer; recurrent prostate cancer
  
• Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00031876 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
  ClinicalTrials.gov Identifier: NCT00087217 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Paclitaxel, Estramustine, and Thalidomide in Treating Patients With Progressive Metastatic Androgen-Independent Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00082693 - Active, not recruiting
  adenocarcinoma of the prostate; recurrent prostate cancer; stage IV prostate cancer
  
• Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
  ClinicalTrials.gov Identifier: NCT00003622 - Active, not recruiting
  stage IV prostate cancer; adenocarcinoma of the prostate; recurrent prostate cancer; Quality of Life
  
• Interferon alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00062010 - Active, not recruiting
  Recurrent Small Cell Lung Cancer
  
• Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors
  ClinicalTrials.gov Identifier: NCT00024310 - Active, not recruiting
  Drug Toxicity; unspecified adult solid tumor, protocol specific
  
• Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00009776 - Active, not recruiting
  Burkitt's Lymphoma; Lymphocytic Lymphoma
  
• Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00003193 - Active, not recruiting
  Oral Cancer; Throat Cancer
  
• Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-small Cell Lung Cancer (NSCLC)
  ClinicalTrials.gov Identifier: NCT00087802 - Active, not recruiting
  Carcinoma, Non-Small-Cell Lung
  
• Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00028990 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer; Male Breast Cancer
  
• Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)
  ClinicalTrials.gov Identifier: NCT00544232 - Active, not recruiting
  Breast Cancer
  
• Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
  ClinicalTrials.gov Identifier: NCT00004067 - Active, not recruiting
  stage II breast cancer; stage IIIA breast cancer
  
• Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00265733 - Active, not recruiting
  Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
  
• Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00006108 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus
  ClinicalTrials.gov Identifier: NCT00003128 - Active, not recruiting
  stage III uterine sarcoma; stage IV uterine sarcoma; recurrent uterine sarcoma; uterine carcinosarcoma
  
• Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
  ClinicalTrials.gov Identifier: NCT00151034 - Active, not recruiting
  Advanced Urothelial Cancer
  
• Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00062179 - Active, not recruiting
  stage IIIA non-small cell lung cancer
  
• Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon alfa in Treating Patients With Recurrent Ovarian Cancer
  ClinicalTrials.gov Identifier: NCT00002734 - Active, not recruiting
  recurrent ovarian epithelial cancer; peritoneal cavity cancer
  
• Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
  ClinicalTrials.gov Identifier: NCT00083057 - Active, not recruiting
  Hypopharyngeal Cancer; Laryngeal Cancer; lip and oral cavity cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; ...
  
• Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00006118 - Active, not recruiting
  stage III bladder cancer; stage IV bladder cancer; transitional cell carcinoma of the bladder
  
• Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00003299 - Active, not recruiting
  extensive stage small cell lung cancer
  
• Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00003717 - Active, not recruiting
  stage IV prostate cancer; adenocarcinoma of the prostate; recurrent prostate cancer; Quality of Life
  
• DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00024375 - Active, not recruiting
  recurrent pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
  ClinicalTrials.gov Identifier: NCT00322452 - Active, not recruiting
  Non-Small Cell Lung Cancer
  
• Paclitaxel With or Without Trastuzumab in Treating Patients With Inoperable, Recurrent, or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00003440 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer; stage IIIB breast cancer
  
• Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00077220 - Active, not recruiting
  stage II non-small cell lung cancer; stage IIIA non-small cell lung cancer; stage IIIB non-small cell lung cancer
  
• Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00006120 - Active, not recruiting
  stage IV breast cancer; stage IIIA breast cancer; recurrent breast cancer; stage IIIB breast cancer
  
• PEPCAD I. The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel
  ClinicalTrials.gov Identifier: NCT00404144 - Active, not recruiting
  Coronary Stenosis
  
• Paclitaxel Coated Balloon Catheter for Prevention of Restenosis in Femoropopliteal Arteries
  ClinicalTrials.gov Identifier: NCT00472472 - Active, not recruiting
  Peripheral Arterial Disease
  
• Paclitaxel(Phyxol) and Cisplatin as First-Line Chemotherapy for Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00154882 - Recruiting
  Breast Cancer
  
• Paclitaxel in Treating Patients With Ovarian Stromal Cancer
  ClinicalTrials.gov Identifier: NCT00006227 - Recruiting
  ovarian stromal cancer
  
• Doxorubicin and Paclitaxel in Treating Women Who are Undergoing Surgery For Breast Cancer
  ClinicalTrials.gov Identifier: NCT00096291 - Active, not recruiting
  stage II breast cancer; stage IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast cancer
  
• Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
  ClinicalTrials.gov Identifier: NCT00002627 - Active, not recruiting
  stage IIIB breast cancer; stage IIIA breast cancer; inflammatory breast cancer; stage II breast cancer